Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, the Chief Development Officer at Corcept Therapeutics Inc., sold approximately $1.85 million worth of shares on August 10, 2026. The transactions comprised 16,300 shares traded at $114.47 each, nearing the stock's 52-week high of $122.21. This sale occurred after a 186% rise in Corcept shares over the past six months.

The stock is currently considered overvalued by InvestingPro, among the most overvalued stocks tracked by the platform. Two separate sales were executed pursuant to a 10b5-1 plan, with the first involving 11,530 shares sold at prices between $112.80 and $113.75, and the second selling 4,770 shares at prices ranging from $113.98 to $114.24.

Both transactions were made pursuant to a previously adopted 10b5-1 plan. Additionally, Guyer used this opportunity to purchase 16,300 shares of Corcept Therapeutics common stock through the exercise of stock options, acquiring them at a price of $21.65 per share. This brought his direct ownership of the company's shares to 3,985, including 1,599 shares from unvested restricted stock awards and 110,000 stock options.

Corcept Therapeutics reported strong second-quarter 2026 financial results, with revenues reaching $256.1 million, a 32% increase from the previous year. The company has also raised its revenue projections for the full year, now expecting between $1.1 billion and $1.2 billion. Analyst H.C. Wainwright has increased its price target for Corcept shares from $95 to $165, maintaining a Buy rating.